Gucci Belt Amazon Uk
The BioChaperone PDGF product has been successfully tested in a phase II clinical trial in India for the treatment of Gucci Belt Amazon Uk diabetic foot ulcers. This product is protected by two families of patents. The first one covers the complexes between BioChaperone polymers and PDGF; the second covers BioChaperone polymers.
Adocia Strengthens Its Diabetic Foot Ulcer Patent Portfolio
and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.
product for the treatment of diabetic foot ulcer. These patents cover the major markets we are targeting.
Adocia develops proprietary products based on doxorubicin and docetaxel, two of the most used anti tumoral treatments, which could greatly benefit from an enhanced intra cellular delivery. Adocia will also propose the DriveIn technology to pharmaceutical companies to optimize the efficacy of their own proprietary molecules.
"We are very pleased with the positive outcome on two of our strategic patent families, especially because they have been granted by the very demanding national American and Japanese patent offices. Our product for treating diabetic foot ulcer is patent protected until at least 2026," said Remi Soula, director of business development and intellectual property at Adocia. "The granting of these patents consolidates our strong portfolio of 22 patent families, of which six have been granted US patents."
The BioChaperone polymers, a proprietary technology specifically developed by Adocia, are covered by the second patent. The US Patent and Trademark Office (USPTO) recently granted this patent. Protection of these BioChaperone polymers is now established in the United States, Australia, China, Russia, France and South Africa. It is valid until September 26, 2027.
are the United States, Australia, Mexico, Russia and South Africa. This patent provides protection until September 26, 2026.
Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes.
Adocia successfully completed two phases I and II studies on the formulation of a fast acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer healing product. Furthermore, in mid November Adocia launched a Phase I clinical trial on a unique combination of fast acting insulin and slow acting insulin, for an optimal insulin therapy with one single product.
"Innovative medicine for everyone, everywhere"
Based on its experience and recognized know how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.
Lyon, France, January 13, 2014 Adocia (Euronext Paris: FR0011184241 ADOC), a biotechnology company specializing in the development of 'best in class' medicines from already approved therapeutic molecules, in particular proteins and oncologic drugs, announces today that it has been granted two patents. The first patent is granted in Japan for the BioChaperone PDGF composition and the second in the United States for the BioChaperone polymer. Both patents will protect Adocia's findings in the field of chronic wound healing, especially for diabetic foot ulcers.
Adocia's therapeutic innovations aim at bringing solutions in a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.
Fight cancer by enhancing oncology treatments targeting
Diabetic foot ulcer is one of the main complications of diabetes. a 55 per cent increase, reaching 70 per cent in emerging countries (International Diabetes Federation). An estimated 15 per cent of diabetic patients will develop diabetic foot ulcer in their life (Ramsey et al, 1999).
"We are actively pursuing the clinical development of the BioChaperone PDGF Hermes Belts For Mens
About diabetic foot ulcer:
The patent on the complexes was granted in Europe and the United States in 2012 (cf. press release of June 13, 2012). The inclusion of Japan now extends the coverage to 29 countries. Twenty three are in Europe and the rest Michael Kors Belts White
Through its BioChaperone(R) state of the art technological platform, Adocia intends to enhance the effectiveness Gucci Belt With Snake
Late in 2013, Adocia acquired an exclusive license on a nanotechnology, which improves oncology treatments efficacy by targeting their action to solid tumors. This nanotechnology, called DriveIn(R), is remarkably efficient in carrying active molecules and delivering them within solid tumors. This new platform in nanotechnology is an exceptional opportunity to enter the oncology market by improving the efficacy of already approved treatments.
This press release contains certain forward looking statements concerning Adocia and its business. Such forward looking statements are based on assumptions that Adocia considers to be reasonable. The forward looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia.
Gucci Belt Amazon Uk
Adidas Hats For Girls
Lv Belt Buckle
Louis Vuitton Belt Buckle Repair
Monogram Louis Vuitton Belt
Armani Belts Price
New Era Mlb Caps
Versace Belt Buckle
Gucci Belt Gold
Belt Lv For Man
Atlanta Braves Caps
Adidas Cap Black And Gold
Louis Vuitton Belt Tan
New Era Anaheim Ducks
Ferragamo Belt On Pants